PDN Post Market, Multicenter, Prospective, Global Clinical Study (PDN-PM)
A Post-Market, Multicenter, Prospective, Global Clinical Study to Evaluate the Real-world Experience of Spinal Cord Stimulation That Includes 10 kHz in the Management of Chronic Intractable Pain Associated With Diabetic Neuropathy.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Manish Bharara, PhD
- Phone Number: 1 (650) 785 1061
- Email: manish.bharara@nevro.com
Study Contact Backup
- Name: Kerry Bradley
- Phone Number: 1-650-251-0005
- Email: bradley@nevro.com
Study Locations
-
-
Alaska
-
Anchorage, Alaska, United States, 99508
- Neuroversion, Inc.
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48108
- Michigan Pain Specialists
-
West Bloomfield, Michigan, United States, 48322
- Henry Ford Health
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Ohio State University Wexner Medical Center
-
-
Oklahoma
-
Edmond, Oklahoma, United States, 73013
- Clinical Investigations, LLC
-
-
Oregon
-
Milwaukie, Oregon, United States, 97222
- Columbia Pain Management
-
-
Pennsylvania
-
York, Pennsylvania, United States, 17402
- WellSpan Interventional Pain Specialists
-
-
Virginia
-
Roanoke, Virginia, United States, 24018
- Virginia Interventional Pain & Spine Centers
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
To participate in the study, patients must meet all the following inclusion criteria:
- Have been clinically diagnosed with diabetes, according to the local country diabetes association guidelines, as well as painful diabetic neuropathy (PDN) of the lower limbs refractory to conventional medical management.
- Average pain intensity (over the last 7 days) of ≥5 out of 10 cm on the Visual Analog Scale (VAS) in the lower limbs at enrollment/baseline.
- The clinical decision has been made to provide treatment using the Nevro Spinal Cord Stimulation that includes 10 kHz therapy prior to enrollment in the study.
- Be willing and capable of giving written informed consent.
- Be willing and able to comply with study-related requirements and procedures and attend all scheduled visits.
Exclusion Criteria:
To participate in the study, patients must not meet any of the following exclusion criteria:
- Have a diagnosis of a lower limb mononeuropathy (e.g., causalgia and tibial or peroneal neuropathies), have had a lower limb amputation other than toes, or have large (≥3 cm) and/or gangrenous ulcers of the lower limbs
- Have a medical condition or diagnosis that is inconsistent with Nevro's SCS System guidelines in the Physician's Manual for the relevant country, or as per standard clinical practice.
- Have a medical condition or pain in other areas, not intended to be treated in this study, that could interfere with study procedures, accurate pain reporting, and/or confound the evaluation of study endpoints, as determined by the Investigator (such as primary headache, fibromyalgia, post-herpetic neuralgia, osteoarthritis, peripheral vascular disease, or small vessel disease).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: IPG Activated
The group of participants who have had a successful trial (>50% pain relief) during the trial phase
|
Spinal cord stimulation system (SCS) is an approved system to manage chronic intractable pain of the limbs and/or leg by delivering electrical stimulation using implantable leads and rechargeable implantable pulse generator (IPG) with 16 output channels.
The IPG is implanted in a subcutaneous pocket and is capable of stimulating the spinal cord nerves when used with one or two 8-contact percutaneous or paddle leads.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Trial success rate/Responder rate
Time Frame: 2 weeks
|
Percentage of patients with a successful trial phase (responder rate) i.e. at least 50% reduction in patient-reported overall pain relief.
|
2 weeks
|
|
Patient-reported overall pain relief
Time Frame: 12 months
|
The average percentage of patient-reported pain relief at 3,6 and 12 months.
|
12 months
|
|
Leg pain
Time Frame: 12 months
|
Leg pain will be assessed using a 10 cm Visual Analog Scale (VAS) with 0 indicating no pain and 10 indicating the worst pain. Following outcome measures will be derived from the VAS score on leg pain.
|
12 months
|
|
Quality of life measure
Time Frame: 12 months
|
Change from baseline in quality of life at 3, 6 and 12 months will be assessed using the EQ-5D-5L questionnaire.
|
12 months
|
|
Pain Inventory
Time Frame: 12 months
|
Change from baseline in pain symptoms at 3, 6 and 12 months assessed by 11-point BPI-DPN (Brief Pain Inventory for Diabetic Peripheral Neuropathy) pain scale, with 0 indicating no pain and 10 indicating worst pain.
|
12 months
|
|
Global impression of change in health status
Time Frame: 12 months
|
The patient's general health status at 3, 6 and 12 months will be assessed both by the patients themselves as well as the study investigators using the 7-point PGIC (Patient Global Impression of Change) and the CGIC (Clinician Global Impression of Change) instrument respectively.
Responses for this questionnaire range from "no change (or condition has got worse)" to "a great deal better".
|
12 months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patients Work Status
Time Frame: 12 months
|
Patients' current work status (working for pay, working without pay, self-employed, out of work for more than 1 year, out of work for less than 1 year, homemaker/taking care of the house and/or family, student, retired, unable to work) will be collected at baseline and repeated at the 12 months follow up visit.
|
12 months
|
|
Device Safety
Time Frame: 12 months
|
Subjects will be assessed for the procedure and device-related adverse events starting at enrollment and continuing through study completion.
An adverse event may include but is not limited to infection, lead revisions, IPG revisions, device malfunction, and explantation of devices.
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: David Caraway, MD, Chief Medical Officer, Nevro Corp
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CA2021-03 INT PDN-PM
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.